Background: Postpartum haemorrhage (PPH) is a major contributor to maternal morbidity and mortality worldwide. Traditional uterotonic agents have limitations, necessitating the exploration of effective alternatives such as carbetocin, a long-acting oxytocin analog. Objective: This study aimed to evaluate the efficacy and safety of carbetocin in preventing PPH in both vaginal and cesarean deliveries. Methods: In this cross-sectional study, 100 women who underwent childbirth (50 vaginal and 50 cesarean deliveries) at a obgy department of multispeciality hospital were administered carbetocin immediately postpartum. The primary outcome was the prevention of PPH, defined as a blood loss of less than 500 mL for vaginal deliveries and less than 1000 mL for cesarean deliveries. Secondary outcomes included the need for additional uterotonics and the occurrence of adverse events. Results: Carbetocin proved highly effective in preventing PPH, with a success rate of 90% in vaginal deliveries and 96% in cesarean deliveries. The need for additional uterotonics was significantly lower in the cesarean group (6%) compared to the vaginal group (20%). Adverse events were minimal, affecting 16% of vaginal deliveries and 10% of cesarean deliveries, indicating a favorable safety profile for carbetocin. Conclusion: Carbetocin is effective and safe for the prevention of PPH in both vaginal and cesarean deliveries. Its use could simplify the management of PPH, reducing the need for additional uterotonics and enhancing overall maternal safety. Further studies with larger and more diverse populations are recommended to confirm these findings and potentially generalize them to broader obstetric practice.